. 2019 Jun 17;36(8):1826–1832. doi: 10.1007/s12325-019-01008-2

Table 1.

Select randomized trials featuring concurrent chemotherapy and immunotherapy

Study	Chemotherapy	Intervention	PFS (months)	PFS HR	OS (months)	OS HR
Reck et al. [23]	Carboplatin plus paclitaxel	Ipilimumab	3.9	0.93 (059–1.48)	9.1	0.89 (0.57–1.39)
Reck et al. [23]	Carboplatin plus paclitaxel	Placebo	5.2	0.93 (059–1.48)	10.5	0.89 (0.57–1.39)
Reck et al. [24]	Platinum plus etoposide	Ipilimumab	4.6	0.85 (0.75–0.97)	11.0	0.94 (0.81–1.09)
Reck et al. [24]	Platinum plus etoposide	Placebo	4.4	0.85 (0.75–0.97)	10.9	0.94 (0.81–1.09)
Horn et al. [25]	Carboplatin plus etoposide	Atezolizumab	5.2	0.77 (0.62–0.96)	12.3	0.70 (0.54–0.91)
Horn et al. [25]	Carboplatin plus etoposide	Placebo	4.3	0.77 (0.62–0.96)	10.3	0.70 (0.54–0.91)